Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

Partner Therapeutics announced the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide.
[Partner Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

Share

Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

Curis, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody.
[Curis, Inc.]
Press Release
Bookmark

No account yet? Register

Share

ECU, Vidant Begin Trial of COVID-19 Treatment

Dr. Paul Cook, chief of the Division of Infectious Diseases at East Carolina Univesity’s Brody School of Medicine, began enrolling patients June 1 in a clinical trial investigating a new treatment aimed at preventing and shortening the duration of Acute Respiratory Distress Syndrome (ARDS). ARDS is a characteristic of COVID-19 that occurs when fluid builds up in the lungs and prevents oxygen from entering the bloodstream.
[East Carolina University]
Full Article
Bookmark

No account yet? Register

Share

Hong Kong’s Contentious National Security Law Concerns Some Academics

China’s plan to introduce a new security law in Hong Kong has prompted mixed reactions from scientists there. Some fear that such a law could lead to government interference in research, restrict participation in international collaborations and increase self-censorship, whereas others are confident that research will be unaffected.
[Nature News]
Editorial
Bookmark

No account yet? Register

Share

City of Hope Signs Licensing Agreement with Scopus BioPharma Inc. to Develop Novel, Targeted Immuno-Oncology Gene Therapy

City of Hope have signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
[City of Hope]
Press Release
Bookmark

No account yet? Register

Share

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

Ovid Therapeutics Inc. announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for a range of rare neurological conditions, complementary to Ovid’s current pipeline.
[Ovid Therapeutics Inc.]
Press Release
Bookmark

No account yet? Register

Share

Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E

Sarepta Therapeutics announced positive results from a study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E.
[Sarepta Therapeutics]
Abstract
Bookmark

No account yet? Register

Share

New Wound-Healing Research Project Wins NASA Tick of Approval

A group of Australian scientists have caught the attention of NASA with a novel technology development that could potentially heal wounds in days rather than weeks without using stitches.
[Southern Cross University]
[zotpress items='{6445212:AXC6GPGE}’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

International Prize Awarded to Two Pieces of Novel Research in the 3Rs

The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi. Marta and colleagues have developed advanced 3D cultures of human and mouse ESCs to mimic the development of the embryo at implantation and the subsequent morphogenesis and formation of the amniotic cavity.
[EurekAlert!]
Press Release
Bookmark

No account yet? Register

Share

As the Pandemic Hits Campus Finances, Faculty Face Layoffs

The pandemic has bored holes in budgets at universities and colleges across the US and beyond. To stem the spread of the coronavirus, higher education institutions shuttered their campuses, sent students home, and moved classes online.
[The Scientist]
Editorial
Bookmark

No account yet? Register

Share
Share